Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Oct 23;13(10):e0205368.
doi: 10.1371/journal.pone.0205368. eCollection 2018.

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Javier Morales-Ramirez  1 , Johannes R Bogner  2 , Jean-Michel Molina  3 , Johan Lombaard  4 , Ira B Dicker  5 , David A Stock  6 , Michelle DeGrosky  5 , Margaret Gartland  7 , Teodora Pene Dumitrescu  8 , Sherene Min  7 , Cyril Llamoso  5 , Samit R Joshi  5 , Max Lataillade  5
Affiliations
Clinical Trial

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Javier Morales-Ramirez et al. PLoS One. .

Abstract

GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer peptide 1 of HIV-1. Study 205891 (previously AI468038) investigated the efficacy, safety, and dose response of GSK3532795 in treatment-naive, HIV-1-infected participants. Study 205891 (NCT02415595) was a Phase IIb, randomized, active-controlled, double-blind, international trial. Participants were randomized 1:1:1:1 to one of three GSK3532795 arms at doses 60 mg, 120 mg or 180 mg once daily (QD), or to efavirenz (EFV) at 600 mg QD, each in combination with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) (300/200 mg QD). Primary endpoint was proportion of participants with plasma HIV-1 RNA <40 copies/mL at Week 24. Between May 2015 and May 2016, 206 participants received treatment. At Week 24, 76-83% participants receiving GSK3532795 and 77% receiving EFV achieved HIV-1 RNA <40 copies/mL. Fifteen participants receiving GSK3532795 and one receiving EFV met resistance testing criteria; 10/15 receiving GSK3532795 had emergent substitutions at reverse transcriptase positions M184, and one at position K65, while the participant receiving EFV did not have any nucleoside reverse transcriptase inhibitor (NRTI)/non-NRTI mutations. EFV, relative to GSK3532795, had more serious adverse events (9% versus 5%) and adverse events leading to discontinuation (17% versus 5%). However, 3-4-fold higher rates of gastrointestinal adverse events were observed with GSK3532795 relative to EFV. GSK3532795 combined with TDF/FTC is efficacious with 24 weeks of therapy. However, GSK3532795 showed a higher rate of gastrointestinal intolerability and treatment-emergent resistance to the NRTI backbone relative to EFV. Trial registration: ClinicalTrials.gov NCT02415595.

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: IBD, CL, SRJ, SM and MD are employees of ViiV Healthcare, ML and MG are employees of ViiV Healthcare and shareholders at GlaxoSmithKline. TPD is an employee of GlaxoSmithKline, J-MM reports advisory boards for Gilead, Merck, ViiV Healthcare, Bristol-Myers Squibb (BMS), Janssen and Teva and grants from Gilead, JM-R reports no conflict of interest, JRB reports personal fees from BMS, ViiV Healthcare, Merck Sharpe and Dohme, Gilead, Janssen and Hexal, DAS was an employee of Bristol-Myers Squibb during conduct of the study. JM-R and JL have no conflicts to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Participant disposition.
AE, adverse event; EFV, efavirenz; QD, once daily; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine.
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Cited 1 November 2017.
    1. AIDSinfo. FDA-approved HIV medicines. Available from: https://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-appro.... Cited 1 November 2017.
    1. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol. 2002;76: 10226–10233. 10.1128/JVI.76.20.10226-10233.2002 - DOI - PMC - PubMed
    1. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998;72: 2846–2854. - PMC - PubMed
    1. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007;9: 162–172. - PubMed

Publication types

MeSH terms

Associated data